Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI
Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Milosevic, Aleksandar [verfasserIn] Chodyla, Michal [verfasserIn] Bruckmann, Nils Martin [verfasserIn] Lindemann, Maike E. [verfasserIn] Grueneisen, Johannes [verfasserIn] Haubold, Johannes [verfasserIn] Fendler, Wolfgang P. [verfasserIn] Umutlu, Lale [verfasserIn] Quick, Harald H. [verfasserIn] Schaarschmidt, Benedikt M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2024 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical and translational imaging - Springer International Publishing, 2013, 12(2024), 4 vom: 25. Apr., Seite 441-448 |
|---|---|
| Übergeordnetes Werk: |
volume:12 ; year:2024 ; number:4 ; day:25 ; month:04 ; pages:441-448 |
| Links: |
|---|
| DOI / URN: |
10.1007/s40336-024-00628-1 |
|---|
| Katalog-ID: |
SPR056945302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR056945302 | ||
| 003 | DE-627 | ||
| 005 | 20240813064816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240813s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40336-024-00628-1 |2 doi | |
| 035 | |a (DE-627)SPR056945302 | ||
| 035 | |a (SPR)s40336-024-00628-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Milosevic, Aleksandar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. | ||
| 650 | 4 | |a Attenuation correction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PET/MRI |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a μmap |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a DOTATOC |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NET imaging |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chodyla, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Bruckmann, Nils Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Lindemann, Maike E. |e verfasserin |4 aut | |
| 700 | 1 | |a Grueneisen, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Haubold, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Fendler, Wolfgang P. |e verfasserin |4 aut | |
| 700 | 1 | |a Umutlu, Lale |e verfasserin |4 aut | |
| 700 | 1 | |a Quick, Harald H. |e verfasserin |4 aut | |
| 700 | 1 | |a Schaarschmidt, Benedikt M. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational imaging |d Springer International Publishing, 2013 |g 12(2024), 4 vom: 25. Apr., Seite 441-448 |w (DE-627)742738752 |w (DE-600)2712000-4 |x 2281-7565 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:25 |g month:04 |g pages:441-448 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40336-024-00628-1 |m X:SPRINGER |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a SYSFLAG_0 | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2056 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 4 |b 25 |c 04 |h 441-448 | ||
| author_variant |
a m am m c mc n m b nm nmb m e l me mel j g jg j h jh w p f wp wpf l u lu h h q hh hhq b m s bm bms |
|---|---|
| matchkey_str |
article:22817565:2024----::matfaoiimaecnrsaetoatnainorcinntaeqatfctoinuonor |
| hierarchy_sort_str |
2024 |
| publishDate |
2024 |
| allfields |
10.1007/s40336-024-00628-1 doi (DE-627)SPR056945302 (SPR)s40336-024-00628-1-e DE-627 ger DE-627 rakwb eng 610 VZ Milosevic, Aleksandar verfasserin aut Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. Attenuation correction (dpeaa)DE-He213 PET/MRI (dpeaa)DE-He213 μmap (dpeaa)DE-He213 DOTATOC (dpeaa)DE-He213 NET imaging (dpeaa)DE-He213 Chodyla, Michal verfasserin aut Bruckmann, Nils Martin verfasserin aut Lindemann, Maike E. verfasserin aut Grueneisen, Johannes verfasserin aut Haubold, Johannes verfasserin aut Fendler, Wolfgang P. verfasserin aut Umutlu, Lale verfasserin aut Quick, Harald H. verfasserin aut Schaarschmidt, Benedikt M. verfasserin aut Enthalten in Clinical and translational imaging Springer International Publishing, 2013 12(2024), 4 vom: 25. Apr., Seite 441-448 (DE-627)742738752 (DE-600)2712000-4 2281-7565 nnns volume:12 year:2024 number:4 day:25 month:04 pages:441-448 https://dx.doi.org/10.1007/s40336-024-00628-1 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2024 4 25 04 441-448 |
| spelling |
10.1007/s40336-024-00628-1 doi (DE-627)SPR056945302 (SPR)s40336-024-00628-1-e DE-627 ger DE-627 rakwb eng 610 VZ Milosevic, Aleksandar verfasserin aut Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. Attenuation correction (dpeaa)DE-He213 PET/MRI (dpeaa)DE-He213 μmap (dpeaa)DE-He213 DOTATOC (dpeaa)DE-He213 NET imaging (dpeaa)DE-He213 Chodyla, Michal verfasserin aut Bruckmann, Nils Martin verfasserin aut Lindemann, Maike E. verfasserin aut Grueneisen, Johannes verfasserin aut Haubold, Johannes verfasserin aut Fendler, Wolfgang P. verfasserin aut Umutlu, Lale verfasserin aut Quick, Harald H. verfasserin aut Schaarschmidt, Benedikt M. verfasserin aut Enthalten in Clinical and translational imaging Springer International Publishing, 2013 12(2024), 4 vom: 25. Apr., Seite 441-448 (DE-627)742738752 (DE-600)2712000-4 2281-7565 nnns volume:12 year:2024 number:4 day:25 month:04 pages:441-448 https://dx.doi.org/10.1007/s40336-024-00628-1 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2024 4 25 04 441-448 |
| allfields_unstemmed |
10.1007/s40336-024-00628-1 doi (DE-627)SPR056945302 (SPR)s40336-024-00628-1-e DE-627 ger DE-627 rakwb eng 610 VZ Milosevic, Aleksandar verfasserin aut Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. Attenuation correction (dpeaa)DE-He213 PET/MRI (dpeaa)DE-He213 μmap (dpeaa)DE-He213 DOTATOC (dpeaa)DE-He213 NET imaging (dpeaa)DE-He213 Chodyla, Michal verfasserin aut Bruckmann, Nils Martin verfasserin aut Lindemann, Maike E. verfasserin aut Grueneisen, Johannes verfasserin aut Haubold, Johannes verfasserin aut Fendler, Wolfgang P. verfasserin aut Umutlu, Lale verfasserin aut Quick, Harald H. verfasserin aut Schaarschmidt, Benedikt M. verfasserin aut Enthalten in Clinical and translational imaging Springer International Publishing, 2013 12(2024), 4 vom: 25. Apr., Seite 441-448 (DE-627)742738752 (DE-600)2712000-4 2281-7565 nnns volume:12 year:2024 number:4 day:25 month:04 pages:441-448 https://dx.doi.org/10.1007/s40336-024-00628-1 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2024 4 25 04 441-448 |
| allfieldsGer |
10.1007/s40336-024-00628-1 doi (DE-627)SPR056945302 (SPR)s40336-024-00628-1-e DE-627 ger DE-627 rakwb eng 610 VZ Milosevic, Aleksandar verfasserin aut Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. Attenuation correction (dpeaa)DE-He213 PET/MRI (dpeaa)DE-He213 μmap (dpeaa)DE-He213 DOTATOC (dpeaa)DE-He213 NET imaging (dpeaa)DE-He213 Chodyla, Michal verfasserin aut Bruckmann, Nils Martin verfasserin aut Lindemann, Maike E. verfasserin aut Grueneisen, Johannes verfasserin aut Haubold, Johannes verfasserin aut Fendler, Wolfgang P. verfasserin aut Umutlu, Lale verfasserin aut Quick, Harald H. verfasserin aut Schaarschmidt, Benedikt M. verfasserin aut Enthalten in Clinical and translational imaging Springer International Publishing, 2013 12(2024), 4 vom: 25. Apr., Seite 441-448 (DE-627)742738752 (DE-600)2712000-4 2281-7565 nnns volume:12 year:2024 number:4 day:25 month:04 pages:441-448 https://dx.doi.org/10.1007/s40336-024-00628-1 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2024 4 25 04 441-448 |
| allfieldsSound |
10.1007/s40336-024-00628-1 doi (DE-627)SPR056945302 (SPR)s40336-024-00628-1-e DE-627 ger DE-627 rakwb eng 610 VZ Milosevic, Aleksandar verfasserin aut Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. Attenuation correction (dpeaa)DE-He213 PET/MRI (dpeaa)DE-He213 μmap (dpeaa)DE-He213 DOTATOC (dpeaa)DE-He213 NET imaging (dpeaa)DE-He213 Chodyla, Michal verfasserin aut Bruckmann, Nils Martin verfasserin aut Lindemann, Maike E. verfasserin aut Grueneisen, Johannes verfasserin aut Haubold, Johannes verfasserin aut Fendler, Wolfgang P. verfasserin aut Umutlu, Lale verfasserin aut Quick, Harald H. verfasserin aut Schaarschmidt, Benedikt M. verfasserin aut Enthalten in Clinical and translational imaging Springer International Publishing, 2013 12(2024), 4 vom: 25. Apr., Seite 441-448 (DE-627)742738752 (DE-600)2712000-4 2281-7565 nnns volume:12 year:2024 number:4 day:25 month:04 pages:441-448 https://dx.doi.org/10.1007/s40336-024-00628-1 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 12 2024 4 25 04 441-448 |
| language |
English |
| source |
Enthalten in Clinical and translational imaging 12(2024), 4 vom: 25. Apr., Seite 441-448 volume:12 year:2024 number:4 day:25 month:04 pages:441-448 |
| sourceStr |
Enthalten in Clinical and translational imaging 12(2024), 4 vom: 25. Apr., Seite 441-448 volume:12 year:2024 number:4 day:25 month:04 pages:441-448 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Attenuation correction PET/MRI μmap DOTATOC NET imaging |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Clinical and translational imaging |
| authorswithroles_txt_mv |
Milosevic, Aleksandar @@aut@@ Chodyla, Michal @@aut@@ Bruckmann, Nils Martin @@aut@@ Lindemann, Maike E. @@aut@@ Grueneisen, Johannes @@aut@@ Haubold, Johannes @@aut@@ Fendler, Wolfgang P. @@aut@@ Umutlu, Lale @@aut@@ Quick, Harald H. @@aut@@ Schaarschmidt, Benedikt M. @@aut@@ |
| publishDateDaySort_date |
2024-04-25T00:00:00Z |
| hierarchy_top_id |
742738752 |
| dewey-sort |
3610 |
| id |
SPR056945302 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR056945302</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240813064816.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240813s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40336-024-00628-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR056945302</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40336-024-00628-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Milosevic, Aleksandar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Attenuation correction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PET/MRI</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">μmap</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DOTATOC</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NET imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chodyla, Michal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bruckmann, Nils Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lindemann, Maike E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grueneisen, Johannes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haubold, Johannes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fendler, Wolfgang P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Umutlu, Lale</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quick, Harald H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schaarschmidt, Benedikt M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical and translational imaging</subfield><subfield code="d">Springer International Publishing, 2013</subfield><subfield code="g">12(2024), 4 vom: 25. Apr., Seite 441-448</subfield><subfield code="w">(DE-627)742738752</subfield><subfield code="w">(DE-600)2712000-4</subfield><subfield code="x">2281-7565</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:4</subfield><subfield code="g">day:25</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:441-448</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40336-024-00628-1</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2024</subfield><subfield code="e">4</subfield><subfield code="b">25</subfield><subfield code="c">04</subfield><subfield code="h">441-448</subfield></datafield></record></collection>
|
| author |
Milosevic, Aleksandar |
| spellingShingle |
Milosevic, Aleksandar ddc 610 misc Attenuation correction misc PET/MRI misc μmap misc DOTATOC misc NET imaging Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI |
| authorStr |
Milosevic, Aleksandar |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)742738752 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2281-7565 |
| topic_title |
610 VZ Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI Attenuation correction (dpeaa)DE-He213 PET/MRI (dpeaa)DE-He213 μmap (dpeaa)DE-He213 DOTATOC (dpeaa)DE-He213 NET imaging (dpeaa)DE-He213 |
| topic |
ddc 610 misc Attenuation correction misc PET/MRI misc μmap misc DOTATOC misc NET imaging |
| topic_unstemmed |
ddc 610 misc Attenuation correction misc PET/MRI misc μmap misc DOTATOC misc NET imaging |
| topic_browse |
ddc 610 misc Attenuation correction misc PET/MRI misc μmap misc DOTATOC misc NET imaging |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Clinical and translational imaging |
| hierarchy_parent_id |
742738752 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Clinical and translational imaging |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)742738752 (DE-600)2712000-4 |
| title |
Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI |
| ctrlnum |
(DE-627)SPR056945302 (SPR)s40336-024-00628-1-e |
| title_full |
Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI |
| author_sort |
Milosevic, Aleksandar |
| journal |
Clinical and translational imaging |
| journalStr |
Clinical and translational imaging |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2024 |
| contenttype_str_mv |
txt |
| container_start_page |
441 |
| author_browse |
Milosevic, Aleksandar Chodyla, Michal Bruckmann, Nils Martin Lindemann, Maike E. Grueneisen, Johannes Haubold, Johannes Fendler, Wolfgang P. Umutlu, Lale Quick, Harald H. Schaarschmidt, Benedikt M. |
| container_volume |
12 |
| class |
610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Milosevic, Aleksandar |
| doi_str_mv |
10.1007/s40336-024-00628-1 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68ga]-dotatoc pet/mri |
| title_auth |
Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI |
| abstract |
Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstractGer |
Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstract_unstemmed |
Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible. © The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| collection_details |
SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
4 |
| title_short |
Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI |
| url |
https://dx.doi.org/10.1007/s40336-024-00628-1 |
| remote_bool |
true |
| author2 |
Chodyla, Michal Bruckmann, Nils Martin Lindemann, Maike E. Grueneisen, Johannes Haubold, Johannes Fendler, Wolfgang P. Umutlu, Lale Quick, Harald H. Schaarschmidt, Benedikt M. |
| author2Str |
Chodyla, Michal Bruckmann, Nils Martin Lindemann, Maike E. Grueneisen, Johannes Haubold, Johannes Fendler, Wolfgang P. Umutlu, Lale Quick, Harald H. Schaarschmidt, Benedikt M. |
| ppnlink |
742738752 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s40336-024-00628-1 |
| up_date |
2024-08-13T04:50:14.634Z |
| _version_ |
1807246546315509760 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR056945302</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240813064816.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240813s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40336-024-00628-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR056945302</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40336-024-00628-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Milosevic, Aleksandar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Impact of gadolinium-based contrast agents on attenuation correction and tracer quantification in neuroendocrine malignancies in [68Ga]-DOTATOC PET/MRI</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Italian Association of Nuclear Medicine and Molecular Imaging 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives To investigate the influence of Gadolinium-based contrast agents (CA) on MR-based attenuation correction (MRAC) in evaluating target lesions in [68Ga]Ga-DOTA-TOC. Methods Twenty-four patients with detectable metastases from neuroendocrine tumors underwent whole-body [68Ga]-DOTATOC PET/MRI for staging purposes. According to a consensus reading, 72 target lesions (primaries and metastases) were selected for measurement of standardized uptake values ($ SUV_{max} $, $ SUV_{peak} $, $ SUV_{mean} $). High-resolution CAIPI-accelerated Dixon 3D VIBE sequences with bone atlas and truncation correction were acquired before and after contrast agent application. PET data were subsequently reconstructed using both resulting μmaps ($ MRAC_{native} $ and $ MRAC_{postCA} $). Each target lesion was assessed in both versions of MRAC-PET utilizing a volume of interest (VOI). Measured values were compared using the Pearson Correlation Coefficient. In addition, a Bland–Altman analysis was performed to determine the limits of agreement (LOA). Results A strong correlation was achieved for the SUV values before and after contrast medium administration ($ SUV_{max} $. 0.99; $ SUV_{peak} $. 0.997; $ SUV_{mean} $. 0.993; p < 0.001). Bland–Altman-analysis, however, showed wider LOA between both PET datasets for $ SUV_{max} $ (4.5 and − 4.7) when compared to $ SUV_{peak} $ (1.7 and − 2.1), and $ SUV_{mean} $ (1.8 and − 2.2). Conclusion No major deviations between the measured values in pre- and post-contrast attenuation-corrected PET images have been observed. Minor alterations may occur due to the application of a contrast medium. This has to be accounted for in patients undergoing repeated PET/MR imaging, especially in the context of therapy monitoring. Advances in knowledge Our lesion-based analysis examines the impact of gadolinium-based contrast agents on attenuation correction of PET/MRI and the subsequent influence on tracer quantification. Our lesion based approach did not found any major differences between both assessments, indicating that any influence on lesion analysis is negligible.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Attenuation correction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PET/MRI</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">μmap</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DOTATOC</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NET imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chodyla, Michal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bruckmann, Nils Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lindemann, Maike E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grueneisen, Johannes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haubold, Johannes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fendler, Wolfgang P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Umutlu, Lale</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quick, Harald H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schaarschmidt, Benedikt M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical and translational imaging</subfield><subfield code="d">Springer International Publishing, 2013</subfield><subfield code="g">12(2024), 4 vom: 25. Apr., Seite 441-448</subfield><subfield code="w">(DE-627)742738752</subfield><subfield code="w">(DE-600)2712000-4</subfield><subfield code="x">2281-7565</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:4</subfield><subfield code="g">day:25</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:441-448</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40336-024-00628-1</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2024</subfield><subfield code="e">4</subfield><subfield code="b">25</subfield><subfield code="c">04</subfield><subfield code="h">441-448</subfield></datafield></record></collection>
|
| score |
7.3993044 |